MAJIC update: promising results for ruxolitinib in PV and ET

Claire Harrison, MD, FRCP, FRCPath, from Guy's and St Thomas' Hospital, London, UK, presented updates and results from the MAJIC clinical trial (ISRCTN61925716) at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. This trial compares the efficacy of JAK inhibitor ruxolitinib with best available care in both essential thrombocythemia (ET) and polycythemia vera (PV). Promising results are coming from this study, with ruxolitinib appearing to yield deep, rapid responses, as well as a reduction in leukemic and myelofibrotic transformation. Dr Harrison also discusses molecular signatures associated with poor outcomes in ET, such as TP53 and SF3B1 mutations, and the fact that ruxolitinib therapy is able to overcome poor outcomes in some of these patients.